Quick Facts

Chemical Name
Bremelanotide
Also Known As
Bremelanotide, Vyleesi
Category
Metabolic & Other
Administration
Subcutaneous injection in the abdomen or thigh, administered as needed

What is PT-141?

PT-141, also known as bremelanotide, is a synthetic peptide analog of alpha-melanocyte stimulating hormone. It is FDA-approved under the brand name Vyleesi for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike PDE5 inhibitors that work on blood flow, PT-141 acts on melanocortin receptors in the brain, making it unique in its mechanism of action.

How Does PT-141 Work?

PT-141 is a non-selective agonist of melanocortin receptors, particularly MC1R, MC3R, MC4R, and MC5R. Its effects on sexual function are primarily mediated through MC4R activation in the central nervous system. This receptor activation influences dopaminergic pathways involved in sexual arousal and desire. The peptide works on the neural component of sexual response rather than peripheral blood flow.

Research-Backed Benefits

Sexual Desire Enhancement

Strong Evidence

FDA-approved for treating low sexual desire in premenopausal women.

Central Nervous System Action

Strong Evidence

Works through brain pathways rather than blood flow, offering a unique mechanism.

Both Genders

Moderate Evidence

Research shows potential benefits for sexual dysfunction in both men and women.

Alternative to PDE5 Inhibitors

Moderate Evidence

Provides an option for those who don't respond to or can't use vascular agents.

Dosage Guidelines

Disclaimer: This content is for educational purposes only. Peptides are research compounds not approved by the FDA for human use. Always consult with a qualified healthcare provider.

Typical Range
1.75 mg (FDA-approved dose for women)
Frequency
As needed, at least 45 minutes before activity
Duration
Single dose as needed

No more than one dose per 24 hours or 8 doses per month recommended.

Side Effects & Safety

  • Nausea (common)
  • Flushing
  • Headache
  • Transient blood pressure elevation
  • Injection site reactions

Frequently Asked Questions

PT-141 works by activating melanocortin receptors in the brain that influence sexual desire and arousal. Unlike Viagra, it doesn't directly affect blood flow.
Yes, PT-141 (Vyleesi) is FDA-approved for treating hypoactive sexual desire disorder (HSDD) in premenopausal women.
While only FDA-approved for women, research has studied PT-141 in men with erectile dysfunction, showing potential benefits particularly for those who don't respond to PDE5 inhibitors.

References

  1. Kingsberg SA, et al. "Bremelanotide for Female Sexual Dysfunctions." Obstetrics & Gynecology, 2019. PMID: 31135737

Get the Complete PT-141 Research Protocol

Join 50,000+ researchers with instant access to our comprehensive peptide resource.

Continue Your Research